Investment Overview - On October 12, 2023, the company approved the establishment of a joint venture with Evonik (China) Investment Co., Ltd. to form "Evonik Blue Biological Technology (Shandong) Co., Ltd." in Huimin County, Shandong Province [2] - The registered capital of the joint venture is RMB 37.5 million, with the company contributing RMB 16.875 million (45%) and Evonik contributing RMB 20.625 million (55%) [2] Termination of Investment - The joint venture and its Qingdao branch will be dissolved and liquidated as per the reconciliation agreement signed on July 31, 2025, due to operational considerations and future business planning [4][5] - The board of directors approved the termination of the investment with a unanimous vote of 5 in favor [5] Reconciliation Agreement Details - The agreement includes the dissolution and liquidation of the joint venture and its Qingdao branch, with both parties agreeing to return relevant patents, technologies, trademarks, and strains to the company [6][8] - A new processing agreement will be signed for continued cooperation in the GHS product field, allowing both parties to independently conduct related business under applicable antitrust laws starting August 1, 2025 [9] Impact on the Company - The dissolution and liquidation of the joint venture are not expected to have a significant adverse impact on the company's operations or financial status [12] - The new agreement framework is anticipated to maintain cooperation in the GHS product area without major disruptions to existing business activities [12]

Investment Overview - The company announced the establishment of a joint venture named "Evonik Blue Biotechnology (Shandong) Co., Ltd." with Evonik (China) Investment Co., Ltd. in October 2023, where its wholly-owned subsidiary, Shandong Blue Biotechnology Co., Ltd., will exclusively produce GHS products for the joint venture through OEM processing [1][2] - The registered capital of the joint venture is RMB 37.5 million, with Shandong Blue contributing RMB 16.875 million [1] Termination of Investment - The joint venture and its Qingdao branch will be dissolved and liquidated as per the reconciliation agreement signed on July 31, 2025, due to the actual operating conditions and future business plans of both parties [2][3] - The board of directors approved the termination of the investment with a unanimous vote of 5 in favor, with no opposition or abstentions [2] Reconciliation Agreement - The reconciliation agreement includes the termination of the previous shareholder and OEM agreements, and the establishment of a liquidation team to handle the dissolution and liquidation processes [3] - The joint venture will return all intellectual property rights related to Shandong Blue, and a new OEM agreement will be signed for GHS product production [3][4] Impact on Company - The dissolution and liquidation of the joint venture are not expected to have a significant adverse impact on the company's operations or financial status, and it will not harm the interests of the company and its shareholders [5] - The new OEM agreement will allow continued cooperation in the GHS product sector without major disruptions to existing business operations [5]

Group 1 - The stock price of Blue Biological (603739) closed at 14.5 yuan, down 1.36%, with a turnover rate of 4.84% and a trading volume of 122,400 hands, amounting to 179 million yuan [1] - The latest financial report shows that for Q1 2025, the company had a total revenue of 310 million yuan, an increase of 8.16% year-on-year, while the net profit attributable to shareholders was 9.5768 million yuan, a decrease of 24.73% year-on-year [1] - The company has a current ratio of 1.042, a quick ratio of 0.858, and a debt-to-asset ratio of 37.92% [1] Group 2 - Blue Biological has made investments in 8 companies and participated in 5 bidding projects [2] - The company holds 44 trademark registrations and 447 patent registrations, along with 16 administrative licenses [2]

青岛蔚蓝生物股份有限公司 证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-032 关于全资子公司对外投资的进展公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 对外投资概述 2023 年 10 月 12 日，青岛蔚蓝生物股份有限公司（以下简称"公司"）召开 了第五届董事会第五次会议，审议通过了《关于全资子公司对外投资成立合资公 司的议案》。公司的全资子公司山东蔚蓝生物科技有限公司（以下简称"山东蔚 蓝"）与赢创（中国）投资有限公司（以下简称"赢创中国"）于 2023 年 10 月 12 日签订了《股东协议》，双方计划在中国山东省滨州市惠民县共同设立一家中 外合资公司，即"赢创蔚蓝生物科技（山东）有限公司"。山东蔚蓝将接受合资 公司的委托，以贴牌加工的方式独家为合资公司生产 GHS 产品。山东蔚蓝与赢创 中国将根据《股东协议》将与 GHS 产品相关的业务注入合资公司，山东蔚蓝有权 从合资公司获得《股东协议》约定的收益。 合资公司的注册资本为人民币 3,750 万元，其中，山东蔚蓝认缴出资人民币 1,687. ...

Group 1 - The animal vaccine sector experienced a decline of 0.96%, ranking among the top losers in the concept sector, with companies like BioShares, Zhongmu, and Pulaike leading the declines [1][2] - Among the animal vaccine stocks, five companies saw price increases, with Luoniushan, Weilan Biology, and Dabeinong rising by 1.42%, 1.38%, and 0.73% respectively [1][2] - The animal vaccine sector faced a net outflow of 218 million yuan from main funds, with 12 stocks experiencing outflows, and six stocks seeing outflows exceeding 10 million yuan [2][3] Group 2 - The top net outflow stock was BioShares, with a net outflow of 128 million yuan, followed by Xianfeng Holdings, Jinhai Biological, and Zhongmu, with net outflows of 41.99 million yuan, 26.07 million yuan, and 25.32 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflow included Dabeinong, Luoniushan, and Weilan Biology, attracting net inflows of 34.95 million yuan, 23.76 million yuan, and 13.06 million yuan respectively [2][3] - The detailed outflow data for the animal vaccine sector shows significant declines in stock prices, with BioShares down by 5.56% and a turnover rate of 11.26% [2][3]

Group 1 - The avian influenza concept sector declined by 0.90%, ranking among the top declines in concept sectors, with leading declines from companies such as Zhijiang Biology, Biological Shares, and Zhongmu Shares [1][2] - Among the 10 stocks that increased in price, Weilan Biology, Lianhuan Pharmaceutical, and Wens Foodstuff were the top gainers, with increases of 1.38%, 0.66%, and 0.53% respectively [1][2] - The avian influenza concept sector experienced a net outflow of 383 million yuan from main funds, with 17 stocks seeing net outflows, and 8 stocks with outflows exceeding 10 million yuan [2][3] Group 2 - The stock with the highest net outflow was Biological Shares, with a net outflow of 128 million yuan, followed by Zhongsheng Pharmaceutical, Taiji Group, and Zhijiang Biology with net outflows of 93.42 million yuan, 35.18 million yuan, and 33.51 million yuan respectively [2][3] - The stocks with the highest net inflows included Wens Foodstuff, Weilan Biology, and Oriental Biology, with net inflows of 16.02 million yuan, 13.06 million yuan, and 7.22 million yuan respectively [2][3] - The avian influenza concept sector's outflow list included Biological Shares, Zhongsheng Pharmaceutical, Taiji Group, and Zhijiang Biology, with respective declines of 5.56%, 0.45%, 0.27%, and 7.07% [2][3]

Group 1 - Datang Power achieved a total on-grid electricity of approximately 123.99 billion kWh for the first half of 2025, a year-on-year increase of 1.30%, with wind and solar power generation increasing by 31.27% and 36.35% respectively [1] - North Self Technology signed an equipment procurement contract with a total amount of 164 million yuan [1] - Jinchuan Co. reported a net profit of 1.38 billion yuan for the first half of 2025, a year-on-year decrease of 8.45%, with operating revenue of 6.96 billion yuan, an increase of 5.55% [1][2] Group 2 - Microchip Biotech expects a revenue of 407 million yuan for the first half of 2025, a year-on-year increase of 35%, and a net profit of approximately 30.06 million yuan, a year-on-year increase of 173% [3] - Zongheng Co. anticipates a revenue of 135 million yuan for the first half of 2025, a year-on-year increase of 61.72%, with a net loss of 34.68 million yuan, reducing losses by 18.34 million yuan compared to the previous year [5] - Tuojing Technology expects a revenue of 1.21 billion to 1.26 billion yuan for the second quarter of 2025, a year-on-year increase of 52% to 58%, with a net profit of 238 million to 247 million yuan, a year-on-year increase of 101% to 108% [7] Group 3 - Star Power reported a net profit of 73.42 million yuan for the first half of 2025, a year-on-year decrease of 13.44%, with total revenue of 1.52 billion yuan, an increase of 13.70% [8] - Xiamen Tungsten reported a net profit of 972 million yuan for the first half of 2025, a year-on-year decrease of 4.41%, with operating revenue of 19.18 billion yuan, an increase of 11.75% [9] - Yikang Pharmaceutical's subsidiary received approval for clinical trials of YKYY029 injection for hypertension [11] Group 4 - Mould Technology received a project designation for luxury car exterior parts, with an expected total sales of 2.044 billion yuan over a five-year lifecycle [13] - Jinzhik Technology won multiple projects from the State Grid and Southern Power Grid, with a total bid amount of 133 million yuan [14] - Changjiang Media plans to use up to 700 million yuan of idle funds to purchase financial products [16] Group 5 - Ningbo Gaofa plans to invest up to 20 million USD to establish a production base in Morocco [20] - Xuantai Pharmaceutical's subsidiary received EU GMP certification for solid dosage production lines [22] - Changhua Group received a project designation for key metal structural components from a domestic new energy vehicle company, with an expected total sales of 235 million yuan over a four-year lifecycle [23]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-031 青岛蔚蓝生物股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》等的相关规定，经农业农村部审 查，批准青岛蔚蓝生物股份有限公司（以下简称"公司"）及全资子公司青岛蔚 蓝至宠生物科技有限公司、青岛动保国家工程技术研究中心有限公司与其他单位 联合申报的"氟康唑搽剂"为四类新兽药，并于近日核发了《新兽药注册证书》 （农业农村部公告第 930 号）。 一、新兽药的基本信息 新兽药名称：氟康唑搽剂 研制单位：青岛蔚蓝至宠生物科技有限公司、南京金盾动物药业有限责任公 司、江苏恒丰强生物技术有限公司、济南广盛源生物科技有限公司、青岛蔚蓝生 物股份有限公司、四川吉星动物药业有限公司、山东慈卫药业有限公司、青岛动 保国家工程技术研究中心有限公司。 注册分类：四类 主要成分：氟康唑 作用与用途：用于治疗犬由犬小孢子菌、石膏样小孢子菌、须癣毛癣菌等真 菌引起的轻、中度皮肤癣菌病。 用法与用量：以氟康唑计。 ...

Core Viewpoint - The company has received approval for a new veterinary drug, which is expected to contribute to business growth [1] Group 1: Product Development - The product "Fluconazole Lotion" has been approved as a Class IV new veterinary drug [1] - The product is specifically designed for the treatment of canine dermatophytosis [1] - The development of this product involved collaboration with Nanjing Jindun Animal Pharmaceutical and other entities [1] Group 2: Financial Investment - The total research and development investment for the new veterinary drug amounted to 1.6443 million yuan [1] - The approval of the new veterinary drug is anticipated to create a new performance growth point for the company [1]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-030 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 单位：万元 上述担保事项已经公司 2025 年 4 月 25 日召开的第五届董事会第十六次会议 审议通过，并经公司于 2025 年 5 月 16 日召开的 2024 年年度股东会批准。具体 内容详见公司分别于 2025 年 4 月 26 日、2025 年 5 月 17 日在上海证券交易所网 站披露的《青岛蔚蓝生物股份有限公司关于 2025 年度对外担保额度预计的公告》 （公告编号：2025-011）、《青岛蔚蓝生物股份有限公司 2024 年年度股东会决议 公告》（公告编号：2025-022）。 （三）担保预计情况 | 担保人 | 被担保人 | 本次担保 | 担保余额 | 担保余额占公司 2024 年 | | --- | --- | --- | --- | --- | | | | 金额 | （含本次） | 经审计净资产的比例 | | ...